10:01 AM EDT, 09/18/2024 (MT Newswires) -- Azitra ( AZTR ) said Wednesday that topically applied ATR-04 for the treatment of moderate to severe epidermal growth factor receptor inhibitor-associated skin rash has received fast track designation from the US Food and Drug Administration.

The company said it plans to start a phase 1/2 clinical trial of ATR-04 by the end of this year.

The FDA's fast track program is designed to facilitate the development and expedite the review of potential therapies to address unmet medical needs.

Shares of the company rose 7.2% in recent trading.

Price: 0.61, Change: +0.04, Percent Change: +7.23